ResMed Inc
(BSP:R1MD34)
R$
368.7
0.14 (0.04%)
Market Cap: 216.49 Bil
Enterprise Value: 218.91 Bil
PE Ratio: 32.69
PB Ratio: 6.97
GF Score: 87/100 Resmed Inc at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Mar 22, 2022 / 05:30PM GMT
Release Date Price:
R$306.86
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
Good afternoon. I'd like to welcome everyone to the first day of the KeyBank Life Sciences MedTech & Investor Forum. My name is Matt Mishan. I'm a senior at MedTech Analyst, and I'm pleased to be joined by ResMed, which is represented today by its CEO, Mick Farrell.
Questions & Answers
Matthew Ian Mishan
KeyBanc Capital Markets Inc., Research Division - VP & Senior Equity Research Analyst
For the audience, I'll start us off, but questions can be submitted directly to me by typing into the box below the video screen, and I can relay.
So Mick, welcome. Thank you for joining us. I'm just going to get right to it and ask how should we think about the Russia-Ukraine and the COVID shutdowns in Asia impacting your ability to kind of ramp supply chain at this point?
Michael J. Farrell
ResMed Inc. - CEO & Director
Yes. Well, look, there are a bunch of factors in the market right now,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot